Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00541307 · ClinicalTrials.gov registry record · NA

GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)

A NA study of Peripheral Vascular Diseases, sponsored by W.L.Gore & Associates.

Completed
Registry status
NA
Development phase
119
Enrollment target
5
Study locations

NCT00541307 is a NA study of Peripheral Vascular Diseases that has completed, run by W.L.Gore & Associates. The registered enrollment target is 119 participants, below the 490-participant average among 19 other Peripheral Vascular Diseases trials with a reported enrollment target (76% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00541307, a NA study of Peripheral Vascular Diseases, has completed, sponsored by W.L.Gore & Associates.

COMPLETED
Registry status
NA
Development phase
119 participants
Enrollment target
5
Study locations

Study Summary

The objective of the study is collect data on the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface in the treatment of chronic Superficial Femoral Artery disease. Device patency at 12 months is the primary endpoint.

Interventions

  • DEVICE Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface

Study Locations (5)

California

  • Tri-City Medical Center - Oceanside

Illinois

  • Mercy Hospital and Medical Center - Chicago

Missouri

  • Columbia Surgical Associates - Columbia

Texas

  • Baylor University Medical Center - Dallas

Wisconsin

  • St. Luke's Medical Center - Milwaukee

Trial Details

FieldValue
Enrollment Target 119 participants
Start Date 2007-10
Est. Completion 2011-06
Phase NA

Sponsor

W.L.Gore & Associates

53 total trials

What the Registry Record Tells You About NCT00541307

The ClinicalTrials.gov registry entry for NCT00541307 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 490-participant average among 19 other Peripheral Vascular Diseases trials with a reported enrollment target (76% lower). The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peripheral Vascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface is the first listed.

NCT00541307 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, Missouri.

Frequently Asked Questions

What is clinical trial NCT00541307 about?

NCT00541307 is a clinical study titled "GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)". The objective of the study is collect data on the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface in the treatment of chronic Superficial Femoral Artery disease. Device patency at 12 months is the primary endpoint.

What is the current status of trial NCT00541307?

This trial is currently completed. It is a NA study. The enrollment target is 119 participants. The study started on 2007-10. Estimated completion is 2011-06.

What conditions does trial NCT00541307 study?

This clinical trial studies the following conditions: Peripheral Vascular Diseases.

What interventions are being tested in trial NCT00541307?

The interventions under investigation include: Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface (DEVICE).

Who is sponsoring clinical trial NCT00541307?

This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00541307 being conducted?

This trial has 5 study locations across California, Illinois, Missouri, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Vascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.